Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.

Clinical pharmacology and therapeutics - 1 Dec 2017

Vanhove T, Bouillon T, de Loor H, Annaert P, Kuypers Drj

Abstract excerpt

Whether the combined use of probe drugs for CYP3A4 and P-glycoprotein can clarify the relative contribution of these proteins to pharmacokinetic variability of a dual substrate like tacrolimus has never been assessed. Seventy renal recipients underwent simultaneous 8-h pharmacokinetic profiles for tacrolimus, the CYP3A4 probe midazolam, and the putative P-glycoprotein probe fexofenadine. Patients were genotyped...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Liver-Specific Organic Anion Transporter 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Midazolam

Share to Multidrug Resistance-Associated Protein 2

Share to Multidrug Resistance-Associated Proteins

Share to Organic Anion Transporters

Share to Solute Carrier Organic Anion Transporter Family Member 1B3

Share to Tacrolimus

Source

Identifiers

PMID: 28437851
DOI: 10.1002/cpt.718

Genes

ABCB1
ABCC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.PMID 28437851Read ↗

In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.Semantic proximity Read ↗

Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers.Semantic proximity Read ↗

In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.Semantic proximity Read ↗

Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.Semantic proximity Read ↗

Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.Semantic proximity Read ↗

Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.Semantic proximity Read ↗

A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients.Semantic proximity Read ↗

The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.Semantic proximity Read ↗

Investigation of pharmacologic interactions between omeprazole and tacrolimus in a membranous nephropathy patient with CYP3A5 nonexpresser: a case report.Semantic proximity Read ↗

Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.Semantic proximity Read ↗

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.